EP0269017A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1987-11-20
•
Granted: —
•
Expires: 2007-11-20
Abstract
Abstract Damage to cells, tissue and other body parts in a mammalian host may be treated with a pharmaceutical composition produced using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The lymphokine or cytotoxin is preferably tumor necrosis factor and the biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a pharmaceutical composition may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
Inventors
- 👤 Robert Zimmermann
- 👤 Benedict Joseph Marafino, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 13:19
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61K38/191; A61P; A61P11/00; A61P25/00; A61P31/00; A61P31/04; A61P35/00; A61P43/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
60 words
A composition suitable for administration to mammalian hosts for therapeutic or prophylactic treatment of biological damage to the host causd by free radical generation, which composition comprises a mixture, in pharmacologically effective amounts, of at least one lymphokine or cytotoxin from a mammalian species and at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor.
Claim 2
Dependent Claim
60 words
A composition suitable for administration to mammalian hosts for therapeutic or prophylactic treatment of biological damage to the host causd by free radical generation, which composition comprises a mixture, in pharmacologically effective amounts, of at least one lymphokine or cytotoxin from a mammalian species and at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor.
Claim 3
Dependent Claim
21 words
The composition according to claim 1 wherein the lymphokine or cytotoxin is interleukin-2, interferon-8, tumor necrosis factor, or colony stimulating factor-1.
Claim 4
Dependent Claim
17 words
The composition according to claim 1 or 2 wherein the lymphokine or cytotoxin is tumor necrosis factor-alpha.
Claim 5
Dependent Claim
58 words
The composition according to any one of claims 1 - 3 wherein the biological modifier is selected from the group consisting of uric acid, buthionine sulphoximine, vitamin E, vitamin C, N-acetyl cysteine, a retinoid, glutathione, metronidazole, aspirin, indomethacin, ibuprofen, nordihydroguaiaretic acid, cis-8, 11, 14-eicosatrien-5-ynoic acid, synthetic prostaglandins, synthetic leukotrienes, and combinations of one or more of these modifiers.
Claim 6
Dependent Claim
17 words
The composition according to any one of claims 1 -2 or 4 wherein the lymphokine is interleukin-2.
Claim 7
Dependent Claim
32 words
The composition according to claim 5 wherein the biological modifier is uric acid and the interleukin-2 is a desalanyl₁ mutein with a serine residue at position 125 of the native interleukin-2 molecule.
Claim 8
Dependent Claim
57 words
Use of pharmacologically effective amounts of at least one lymphokine or cytotoxin from a mammalian species and at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of biological damage to a mammalian host caused by free radical generation.
Claim 9
Dependent Claim
57 words
Use of pharmacologically effective amounts of at least one lymphokine or cytotoxin from a mammalian species and at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of biological damage to a mammalian host caused by free radical generation.
Claim 10
Dependent Claim
59 words
The use of at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor for the production of a pharmaceutical composition for enhancing the therapeutic index of at least one lymphokine or cytotoxin from a mammalian species in the therapeutic or prophylactic treatment of biological damage to a mammalian host caused by free radical generation.
Claim 11
Dependent Claim
59 words
The use of at least one biological modifier selected from a free radical scavenger or a metabolic inhibitor for the production of a pharmaceutical composition for enhancing the therapeutic index of at least one lymphokine or cytotoxin from a mammalian species in the therapeutic or prophylactic treatment of biological damage to a mammalian host caused by free radical generation.
Claim 12
Dependent Claim
31 words
Use according to claim 7 or 8 wherein the lymphokine or cytotoxin is selected from the group consisting of an interleukin, an interferon, tumor necrosis factor, or a colony stimulating factor.
Claim 13
Dependent Claim
27 words
Use according to any one of claims 7 - 9 wherein the biological damage is cancer, infection, or damage caused by high oxygen tension, radiotherapy or chemotherapy.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.